Evaluation for the effectiveness and safety for Autologous Bone Marrow Cell infusion (ABMi) therapy for HCV infected liver cirrhosis patient.
- Conditions
- HCV infection, Liver cirrhosis
- Registration Number
- JPRN-UMIN000011651
- Lead Sponsor
- Yamaguchi University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 34
Not provided
(1) Liver cirrhosis induced by other factor without HCV infection and unknown reasons (2) have a malignant neoplasm, or a history of malignant neoplasm (Including HCC) (3) have risk of Esophageal or/and gastric varices (4) Renal dysfunction with 2mg/dL or higher serum creatinine (5) hemoglobin under 8g/dL or Platelets under 50/mL or Prothrombin activity under 40% (6) Total bilirubin 3.0mg/dL or more (7) Performance Status 3 or 4 (8) Cases that cannot obtain the informed consent to autologous blood transfusion (9) undeniable possibility for HBV infection, HIV infection, ATL infection, human parvovirus B19 infection (10) Pregnancy (11) not fit for general anesthesia (12) have a severe allergic reaction to contrast dye or a history of a severe allergic reaction to contrast dye (13) other conditions that doctor considered not suitable for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of Child-Pugh score at 24 weeks after ABMi therapy and control
- Secondary Outcome Measures
Name Time Method